IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

NCT05551507 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer

Interventions

DRUG: IN10018 in combination with PLD

Sponsor

InxMed (Shanghai) Co., Ltd.